Product Reporting Sample Clauses

Product Reporting. Performance Target: MSA-Type – QLSP-POTS QLSP-POTS (No Dispatch) 5 Hours QLSP-POTS (Dispatched) 14 Hours Zone-Type - Availability: Performance will be measured beginning in the first full month of QLSP service (for the following month’s reporting). Notes:
Sample 1Sample 2Sample 3See All (8)
AutoNDA by SimpleDocs
Product Reporting. (a) DIAMETRICS will maintain MDR and other product performance monitoring systems for the Products (excluding Portal Products), and PHILIPS will maintain MDR and other product performance monitoring systems for Portal Products. The Distributing Party shall cooperate with the Manufacturing Party in connection with the Manufacturing Party's obligations under this Section 7.3. The Distributing Party shall provide to the Manufacturing Party, the necessary reports relating to complaints and product performance issues relating to the Products on a timely basis to permit the reporting party to fulfill its regulatory obligations. Notwithstanding the foregoing, upon the execution of a Country Transition Letter, DIAMETRICS shall become responsible for complaint handling in that country, as set forth in the Service and Support Agreement attached hereto as Exhibit 2.2. Upon reasonable request by the Manufacturing Party, the Distributing Party shall promptly make such reports (on behalf of the Manufacturing Party, if appropriate) directly to the appropriate regulatory authorities.
Sample 1Sample 2Sample 3See All (4)
Product Reporting. MSA-Type— QPP-POTS Reported As: Average business days Zone-Type— Performance Target: QPP-POTS (Dispatched) 6 Days QPP-POTS (No Dispatch) 3.5 Days Availability: Notes: Performance can be measured beginning in August 2004 (to be reflected on September 2004 reporting) or the first full month of QPP service (for the following month's reporting), whichever is later. 1. According to this definition, the Applicable Due Date can change, per successive CLEC-initiated due date changes or delays, up to the point when a Qwest-initiated due date change occurs. At that point, the Applicable Due Date becomes fixed (i.e., with no further changes) as the date on which it was set prior to the first Qwest-initiated due date change, if any. Following the first Qwest-initiated due date change, any further CLEC-initiated due date changes or delays are measured as time intervals that are subtracted as indicated in the formula. These delay time intervals are calculated as stated in the description. (Though infrequent, in cases where multiple Qwest-initiated due date changes occur, the stated method for calculating delay intervals is applied to each pair of Qwest-initiated due date change and subsequent CLEC-initiated due date change or delay. The intervals thus calculated from each pairing of Qwest and CLEC-initiated due dates are summed and then subtracted as indicated in the formula.) The result of this approach is that Qwest-initiated impacts on intervals are counted in the reported interval, and CLEC-initiated impacts on intervals are not counted in the reported interval. OOS24-1—Out of Service Cleared within 24 Hours Purpose: Evaluates timeliness of repair for specified services, focusing on trouble reports where the out-of-service trouble reports were cleared within the standard estimate for specified services (i.e., 24 hours for out-of-service conditions).
Sample 1Sample 2Sample 3
Product Reporting. MSA-Type— Performance Targets: • QPP POTS Dispatch and Non-Dispatch 90% Zone-Type— Availability: Notes: Performance can be measured beginning in August 2004 (to be reflected on September 2004 reporting) or the first full month of QPP service (for the following month's reporting), whichever is later. MTTR-1—Mean Time to Restore Purpose: Evaluates timeliness of repair, focusing how long it takes to restore services to proper operation. Description: Measures the average time taken to clear trouble reports. • Includes all trouble reports closed during the reporting period, subject to exclusions specified below. • Includes customer direct reports, customer-relayed reports, and test assist reports that result in a trouble report. • Time measured is from date and time of receipt to date and time trouble is cleared.
Sample 1Sample 2Sample 3
Product Reporting. Performance Target: MSA Type: • QPP-POTS Diagnostic Zone Type: • Availability: Notes: Performance can be measured beginning in August 2004 (to be reflected on September 2004 reporting) or the first full month of QPP service (for the following month's reporting), whichever is later. Qwest Platform Plus™ (QPP™) Rate Sheet - Arizona USOC Recurring Non-Recurring Notes
Sample 1Sample 2Sample 3
Product Reporting. Standards:  Resale Residential single line service Parity with retail service  Sub-Loop Unbundling Parity with retail DS1 Private LineUnbundled Loops: Analog Loop Parity with retail Res & Bus POTS with dispatch 2-Wire Non-Loaded Loop Parity with retail ISDN BRI (designed) DS1-Capable Loop Parity with retail DS1 xDSL-I Capable Loop Parity with retail DS1 Private Line ADSL-Compatible Loop Parity with retail ISDN BRI (designed)  Enhanced Extended Loops-DS1 (EEL-DS1) Parity with retail DS1 Private Line  LIS Trunks Parity with Feature Group D (aggregate)
Sample 1Sample 2
Product Reporting. PO – 6A & 6B Aggregate reporting for all products ordered through IMA-GUI and, separately, IMA-EDI (see disaggregation reporting). Standard: 6 hours Availability: Available Notes: 1. The time a notice is “made available” via the IMA-GUI is the time Qwest stores a status update related to the completion notice in the IMA Status Updates database. When this occurs, the notice can be immediately viewed by the CLEC using the Status Updates window or by using the LSR Notice Inquiry function. Purpose: To evaluate the timeliness with which electronic billing completion notifications are made available or transmitted to CLECs, focusing on the percentage of notifications that are made available or transmitted (for CLECs) or posted in the billing system (for Qwest retail) within five business days.
Sample 1
AutoNDA by SimpleDocs
Product Reporting. Performance Target:
Sample 1
Product Reporting. COMPANY will maintain MDR and other product performance monitoring systems for the Products. In addition to its obligations under Section 5.5, DISTRIBUTOR shall cooperate with COMPANY in connection with its obligations under this Section 6.4 and provide to COMPANY, on a timely basis to permit COMPANY to fulfill its regulatory obligations, the necessary reports relating to complaints and product performance issues relating to the Products. Upon reasonable request by COMPANY, DISTRIBUTOR shall promptly make such reports (on behalf of COMPANY, if appropriate) directly to the appropriate regulatory authorities. In addition, DISTRIBUTOR shall maintain sales and service records to assist it in locating Products for the purpose of implementing recalls and other corrective actions. If COMPANY implements a recall or corrective action in accordance with Section 6.5, DISTRIBUTOR shall provide such location information to COMPANY unless DISTRIBUTOR implements such recall or corrective action itself. In addition, within thirty (30) days after the Effective Date, the Parties shall establish an appropriate notification, consultation and escalation procedure, to be used during the Exclusivity Period, for adverse events relating to the Products, which procedure will permit either Party to take actions consistent with its own regulatory guidelines and criteria, if the Parties cannot mutually agree on a course of action or if the notifying Party is unable to contact the appropriate senior management of the other Party through the notification process. DISTRIBUTOR and COMPANY shall each be responsible for bearing their own costs associated with all product tracking, complaint analyses and related evaluations.
Sample 1

Related to Product Reporting

  • Adverse Event Reporting Both Parties acknowledge the obligation to comply with the Protocol and / or applicable regulations governing the collection and reporting of adverse events of which they may become aware during the course of the Clinical Trial. Both Parties agree to fulfil and ensure that their Agents fulfil regulatory requirements with respect to the reporting of adverse events.

  • Product Recall (a) If a recall is required by applicable Law, or if Buyer or Supplier reasonably determines that a recall is advisable because the goods may create a potential safety hazard, are not in compliance with any applicable code, standard or legal requirement, or contain a defect or non-conformance with the requirements of this Order occurring or likely to occur in multiple goods, which such defects or non-conformances are substantially similar or have substantially similar causes or effects (collectively a “Serial Defect”), the parties shall promptly communicate such facts to each other. At Buyer’s request, Supplier shall promptly develop a corrective action plan satisfactory to Buyer, which shall include all actions required to recall and/or repair the goods and any actions required by applicable Law (“Corrective Action Plan”) for Buyer’s review and approval. At Buyer’s election, Xxxxx may develop the Corrective Action Plan. In no event shall Buyer and Supplier’s failure to agree on the Corrective Action Plan delay the timely notification of a potential safety hazard, non-compliance or Serial Defect to users of the goods, cause either party to be non-compliant with applicable Law or prevent Buyer from taking reasonable actions to prevent injury or damage to persons, equipment or other property. Supplier and Buyer shall cooperate with and assist each other in any corrective actions and/or filings, if applicable.

  • Product Recalls The Company is not aware of any pattern or series of claims against the Company or any of its subsidiaries which reasonably could be expected to result in a generalized product recall relating to products sold by the Company or any of its subsidiaries, regardless of whether such product recall is formal, informal, voluntary or involuntary.

  • Regulatory Reporting Ultimus agrees to provide reports to the federal and applicable state authorities, including the SEC, and to the Funds’ Auditors. Applicable state authorities are those governmental agencies located in states in which the Fund is registered to sell shares.

  • Product Returns Client will have the responsibility for handling customer returns of the Products. Patheon will give Client any assistance that Client may reasonably require to handle the returns.

  • Monthly Reporting Within twenty (20) calendar days following the end of each calendar month, Registry Operator shall deliver to ICANN reports in the format set forth in Specification 3 attached hereto (“Specification 3”).

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, Registration Statement, the Pricing Disclosure Package or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with applicable laws, rules, regulations and policies of the Food and Drug Administration of the U.S. Department of Health and Human Services (the “FDA”) or any committee thereof or of any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are materially inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Pricing Disclosure Package or the Prospectus; for such studies that have been or are being conducted, the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by foreign government or drug or medical device regulatory agencies, or foreign health care facility Institutional Review Boards; and no investigational new drug application filed by or on behalf of the Company or any of its subsidiaries with the FDA has been terminated or suspended by the FDA, and neither the FDA nor any applicable foreign regulatory agency has commenced, or, to the knowledge of the Company, threatened to initiate, any action to place a clinical hold order on, or otherwise terminate, delay or suspend, any proposed or ongoing studies conducted or proposed to be conducted by or on behalf of the Company or any of its subsidiaries.

  • Product Quality 4.1 The following provisions shall apply to Product after Production:

  • Information Reporting (a) The Fund agrees that, during the Current Special Rate Period and so long as BANA or any Affiliate thereof is the beneficial owner of any Outstanding VRDP Shares, it will deliver, or direct the Tender and Paying Agent to deliver, to BANA and any such Affiliate:

  • Regulatory Compliance Cooperation (a) CIT/VC agrees to use commercially reasonable best efforts to avoid the occurrence of a Regulatory Problem. In the event that CIT/VC determines that it has a Regulatory Problem, the Company agrees to use commercially reasonable efforts to take all such actions as are reasonably requested by CIT/VC in order (A) to effectuate and facilitate any transfer by CIT/VC of any Securities of the Company then held by CIT/VC to any Person designated by CIT/VC (subject, however, to compliance with Section 3 of this Agreement), (B) to permit CIT/VC (or any Affiliate of CIT/VC) to exchange all or any portion of the voting Securities of the Company then held by such Person on a share-for-share basis for shares of a class of non-voting Securities of the Company, which non-voting Securities shall be identical in all respects to such voting Securities, except that such new Securities shall be non-voting and shall be convertible into voting Securities on such terms as are requested by CIT/VC in light of regulatory considerations then prevailing, and (C) to continue and preserve the respective allocation of the voting interests with respect to the Company arising out of CIT/VC's ownership of voting Securities of the Company and/or provided for in this Agreement before the transfers and amendments referred to above (including entering into such additional agreements as are requested by CIT/VC to permit any Person(s) designated by CIT/VC to exercise any voting power which is relinquished by CIT/VC upon any exchange of voting Securities for nonvoting Securities of the Company); and the Company shall enter into such additional agreements, adopt such amendments to this Agreement, the Company's Charter and the Company's By-laws and other relevant agreements and taking such additional actions, in each case as are reasonably requested by CIT/VC in order to effectuate the intent of the foregoing. If CIT/VC elects to transfer Securities of the Company to a Regulated Holder in order to avoid a Regulatory Problem, the Company shall enter into such agreements with such Regulated Holder as it may reasonably request in order to assist such Regulated Holder in complying with applicable laws, and regulations to which it is subject. Such agreements may include restrictions on the 39. redemption, repurchase or retirement of Securities of the Company that would result or be reasonably expected to result in such Regulated Holder holding more voting securities or total securities (equity and debt) than it is permitted to hold under such laws and regulations.

Time is Money Join Law Insider Premium to draft better contracts faster.